CD274 and non-small cell lung carcinoma: The use of anti-PD-1/PDL-1 resulted in better outcome both in men and women (HR 0.69, 95% CI 0.62–0.78, p < 0.001 and HR 0.73, 95% CI 0.60–0.89, p = 0.002, respectively), even when the NSCLC subgroup (including 6 studies) was separately considered (HR 0.73, 95% CI 0.63–0.84, p < 0.001 for men and HR 0.66, 95% CI 0.48–0.91, p = 0.011 for women) (Figure 3A,B).